+

WO2013033019A1 - Procédés de détermination de l'intégrité d'un échantillon biologique - Google Patents

Procédés de détermination de l'intégrité d'un échantillon biologique Download PDF

Info

Publication number
WO2013033019A1
WO2013033019A1 PCT/US2012/052519 US2012052519W WO2013033019A1 WO 2013033019 A1 WO2013033019 A1 WO 2013033019A1 US 2012052519 W US2012052519 W US 2012052519W WO 2013033019 A1 WO2013033019 A1 WO 2013033019A1
Authority
WO
WIPO (PCT)
Prior art keywords
sentinel
rna
rnas
degradation
biological sample
Prior art date
Application number
PCT/US2012/052519
Other languages
English (en)
Inventor
Curt HAGEDORN
Original Assignee
University Of Utah Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Utah Research Foundation filed Critical University Of Utah Research Foundation
Publication of WO2013033019A1 publication Critical patent/WO2013033019A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection

Definitions

  • compositions, methods and kits relate broadly to the identification of nucleic acids for determining the overall quality of a biological test sample.
  • the compositions, methods and kits relate to assessing the quantity and processive degradation of nucleic acid molecules as a measure of test sample integrity.
  • RNA sample arrays facilitate the determination of nucleic acid expression levels, which can serve as diagnostic or prognostic indicators of disease.
  • Such tests are clinically employed to aid in the selection of appropriate treatment regimens for patients with various disease indications, such as, e.g., cancer.
  • accurate measures of gene expression can be critical to ensure that the proper therapy is chosen or diagnosis is established.
  • Biological test samples are routinely collected, stored and/or processed under suboptimal conditions for maintaining intact oligonucleotides, e.g., samples may be subjected to room temperature for extended periods of time subsequent to collection.
  • RNases are ubiquitous in biological samples and therefore samples containing RNA are susceptible to degradation. It follows that, if the quality of isolated RNA is compromised, i.e., from a degraded sample, then inaccurate expression profiles may result. Consequently, medical practitioners may prescribe improper treatment protocols or diagnoses based on inaccurate data.
  • compositions, methods and kits for detecting and quantifying nucleic acid markers which serve as a measure of biological sample integrity.
  • the methods described herein measure the quantity and intactness, i.e., level of degradation, of representative RNAs as a conduit for determining the overall quality of a biological test sample.
  • representative RNAs are abundantly expressed and processively degrade with 3 '-5' polarity.
  • methods for determining the integrity of a biological sample include identifying one or more sentinel RNAs in the biological sample, determining the amount of degradation in the one or more sentinel RNAs, comparing the amount of degradation to a reference standard, and correlating the degradation to the integrity of the biological sample.
  • the biological sample includes one or more of blood, plasma, serum, lymph, mucus, sputum, tears, urine, stool, saliva, tissue, hair, animal cells, and plant cells.
  • the one or more sentinel RNAs are mRNA.
  • the one or more sentinel RNAs include one or more of EIF4G2, STOM, C4BPA, GNB1, TMEM66, NAGS, CALM2, ACTG1, AGT, EIF1, SCARB1, C20orf3, CNDP2, CD81, ATP5B, AGXT, EIF4A1, HSP90AB1, AHSG, SARS, CDKN1A, SEPHS2, PSAP, RPL5, TGFBI, CPB2, CCND1, AP2M1, ERGIC3, IBTK, YIF1A, ENOl, UGT2B4, GABARAPL1, KDELR2, RHBDD2, CD63, F9, TRAM1, DHRS3, ZCCHC24, SNRPB, LPCAT3, B2M, ITIH3, RPLP0, CRAT, SERPINA5, ATP5C1, RPL13A,
  • the amount of degradation includes one or more selected from the group consisting of: 3 '-5' processive degradation, 5 '-3 ' processive degradation, a ratio of 3 '-5' processive degradation to 5 '-3' processive degradation, and a ratio of 5 '-3 ' processive degradation to 3 '-5' processive degradation.
  • the 3 '-5 ' processive degradation is determined from 200 nucleotides from the 3 '-end of the one or more sentinel RNAs.
  • the 5 '-3' processive degradation is determined from 200 nucleotides from the 5 '-end of the one or more sentinel RNAs.
  • measuring is by RNA sequencing.
  • the measuring is by quantitative PCR.
  • the quantitative PCR is performed using primers specific for the one or more sentinel RNAs including one or more of EIF4G2, STOM, C4BPA, GNB1, TMEM66, NAGS, CALM2, ACTG1, AGT, EIF1, SCARB1, C20orf3, CNDP2, CD81, ATP5B, AGXT, EIF4A1, HSP90AB1, AHSG, SARS, CDKNIA, SEPHS2, PSAP, RPL5, TGFBI, CPB2, CCND1, AP2M1, ERGIC3, IBTK, YIF1A, ENOl, UGT2B4, GABARAPL1, KDELR2, RHBDD2, CD63, F9, TRAM1, DHRS3, ZCCHC24, SNRPB, LPCAT3, B2M, ITIH3, RPLP0, C
  • a reference standard is included.
  • the reference standard comprises a known amount of sentinel RNA degradation from a control biological sample.
  • the amount of degradation is measured at one or more time points.
  • the indentifying comprises isolating 5 '-capped RNA in the biological sample and determining the level of degradation at one or more time points.
  • a sentinel R A panel is provided.
  • the panel includes SERPINA3, B2M, ENOl, GNB2L1, TMBIM6, PFN1, MYL6, SAA2, JUNB and TIMP1.
  • a method of identifying one or more sentinel RNAs in a biological sample includes isolating RNA from one or more abundantly expressed genes in the biological sample, measuring processive degradation of the isolated RNA at one or more time points; and classifying the one or more abundantly expressed genes as the one or more sentinel RNAs based on the measuring.
  • the isolated RNA is 5 '-capped RNA.
  • the isolated RNA is mRNA.
  • the processive degradation includes one or more of: 3 '-5' processive degradation, 5 '-3' processive degradation, a ratio of 3 '-5' processive degradation to 5 '-3' processive degradation, and a ratio of 5 '-3' processive degradation to 3 '-5 ' processive degradation.
  • the 3 '-5' processive degradation is from 200 nucleotides from the 3'- end of the one or more sentinel RNAs.
  • the 5 '-3' processive degradation is from 200 nucleotides from the 5 '-end of the one or more sentinel RNAs.
  • a control or standard is included.
  • the control comprises RNA.
  • the processive degradation is rapid compared to the processive degradation from a control RNA.
  • the measuring is by RNA sequencing. Additionally or alternatively, in some embodiments, the measuring is by quantitative PCR.
  • the sentinel RNA includes one or more of EIF4G2, STOM, C4BPA, GNB1, TMEM66, NAGS, CALM2, ACTG1,
  • AHSG AHSG, SARS, CDKN1A, SEPHS2, PSAP, RPL5, TGFBI, CPB2, CCND1, AP2M1,
  • the quantitative PCR is performed using primers specific for one or more sentinel RNAs.
  • the sentinel RNAs include one or more of EIF4G2, STOM, C4BPA, GNB1, TMEM66, NAGS, CALM2, ACTG1, AGT, EIF1, SCARB1, C20orf3, CNDP2, CD81, ATP5B, AGXT, EIF4A1, HSP90AB1, AHSG, SARS, CDKN1A, SEPHS2, PSAP, RPL5, TGFBI, CPB2, CCND1, AP2M1, ERGIC3, IBTK, YIFIA, ENOl, UGT2B4, GABARAPLl, KDELR2, RHBDD2, CD63, F9, TRAMl, DHRS3, ZCCHC24, SNRPB, LPCAT3, B2M, ITIH3, RPLP0, CRAT, SERPINA5, ATP5C1, RPLl 3 A, LBP
  • the biological sample includes one or more of blood, plasma, serum, lymph, mucus, sputum, tears, urine, stool, saliva, tissue, hair, animal cells, and plant cells.
  • kits for testing the integrity of a biological sample are provided.
  • the kit includes one or more primers specific for one or more sentinel RNAs, optionally, reagents for qPCR or RNA sequencing; and degradation reference standards.
  • the kit the primers are specific for the one or more sentinel RNAs including one or more of EIF4G2, STOM, C4BPA, GNB1, TMEM66, NAGS, CALM2, ACTG1, AGT, EIF1, SCARB1, C20orO, CNDP2, CD81, ATP5B, AGXT, EIF4A1, HSP90AB1, AHSG, SARS, CDKN1A, SEPHS2, PSAP, RPL5, TGFBI, CPB2, CCND1, AP2M1, ERGIC3, IBTK, YIF1A, ENOl, UGT2B4, GABARAPL1, KDELR2, RHBDD2, CD63, F9, TRAM1, DHRS3, ZCCHC24, SNRPB, LPCAT3, B2M, ITIH3, RPLP0, CRAT, SERPINA5, ATP5C1, RPL13A, LBP, GSDMD, ALB, CLNS1A, ARF1, ND
  • the kit comprises PCR primers for sentinel RNAs
  • FIGURE 1 is a series of graphs showing RNA integrity analyses from frozen donor liver biospecimens that were incubated at room temperature (RT) at increase time intervals (0, 5, 10 or 15 minutes).
  • RT room temperature
  • RIN RNA integrity Number
  • FIGURE 2 is a graph showing the percent of protein coding mRNAs with a >50% reduction in the total number of exonic sequencing reads or RPKM (reads per kilobase of gene per million reads) as samples (same as in FIGURE 1) were allowed to thaw at room temperature for 5, 10, and 15 minutes. A >50% reduction in sequencing reads was observed in 2.7% of mRNA transcripts by 5 minutes, 14% at 10 minutes, and 76% by 15 minutes.
  • FIGURE 3 is a graph showing the percent of protein coding mRNAs with >50, >75, and >90%> of their 0 minute sequencing reads after 5, 10, and 15 minutes.
  • FIGURE 4A-4D shows Integrated Genome Browser images showing RNA-seq reads of representative rapidly and slowly degrading mRNAs, isolated from flash frozen human liver directly (0 minutes), and after 5, 10, and 15 minutes at room temperature. Each vertical black bar represents the total number of reads for a 36 nucleotide sequence, originated from 5' capped RNA, and aligned with the corresponding genomic region.
  • Rapidly degrading transcripts PFNl and JUNB (Panel A and B), showed a rapid decrease in number of reads, particularly at the 3' end, as time increased.
  • JUNB showed a 33, 60, and 78% reduction in 3' reads after 5, 10 and 15 minutes, respectively.
  • PFN1 showed a 39, 66, and 86% reduction after 5, 10 and 15 minutes).
  • HIST1H1E Panel C
  • MT-BCOl Panel D
  • FIGURE 5 is a graph showing the integrity of protein coding Pol II RNAs as measured by sequencing 200 bp of their 3' and 5' ends.
  • the RNA-seq data from the experiment described in Figure 1 and Materials and Methods was further analyzed with informatics programs.
  • To calculate a 375' ratio for each RNA transcript the number of sequence reads from the last 200 bases (3' end) was divided by the reads from the first 200 bases (5' end) of each mRNA transcript and graphed according to time.
  • Protein coding mRNAs with a minimum 5' end RPKM > 10 at all time points were included in the analysis to avoid confounding the analysis with genes with very low expression levels.
  • FIGURE 6 show pie charts of mappable Pol II RNA sequencing reads in intronic, exonic, and intergenic regions over time. The percentage of sequencing reads mapping to exonic, intronic, and intergenic regions at 0, 5, 10, and 15 minutes are shown schematically. With increasing time fewer reads were aligned to exonic regions, but not to intronic or intergenic RNAs. For each pie chart, the largest section is exons; the second largest section is introns and the smallest is intergenic.
  • FIGURE 7A-7J are graphs showing RNA-sequence and 375' qRT-PCR data of sentinel mRNAs with time.
  • RNA-sequence data for five sentinel mRNAs mined from the database obtained from the biospecimens described in Figure 1 are presented.
  • B2M Panel A, B
  • SERPINA3 Panel C, D
  • GNB2L1 Panel E, F
  • TMBIM6 Panel G, H
  • ENOl Panel I, J
  • the RNA-sequence data is presented as in Figure 4.
  • FIGURE 8A-8E are graphs showing RNA-sequence data of other sentinel mRNAs with time.
  • FIGURE 9A-9B are graphs showing examples of control mRNAs that exhibit little degradation with time.
  • the RNA-sequence reads for MT-C01 (9 A) are shown as in Figure 7 and the 375' qPCR ratio (9B) is shown below.
  • the RNA-sequence reads for HIST1H1E ( Figure 4C) another sequence that shows slow or no degradation, is also shown herein.
  • FIGURE 10A-C are graphs showing 375 ' end ratios of B2M(A), GNB2L 1 (B) and TMB1M6(C) sentinel mRNAs at different time points (0, 5, 10 and 15 minutes) as determined by qPCR. Samples were total RNA that had ribosomal RNA removed. Values represent mean 375' ratios ⁇ SEM of three replicates at each time.
  • sentinel RNAs amplification, and quantification of representative nucleic acids, e.g., sentinel RNAs, which can be used to quickly and accurately measure the usefulness and reliability of a biological sample by linking sentinel RNA integrity, e.g., intactness and/or degradation levels, to biological sample quality.
  • the methods can be performed in a multiplex format which permits the determination of expression levels for two or more sentinel RNAs in a single reaction.
  • oligonucleotide includes a plurality of oligonucleotide molecules, and a reference to "a nucleic acid” is a reference to one or more nucleic acids.
  • a nucleic acid is a reference to one or more nucleic acids.
  • 3'-end or “3'-region” refer to the portion of a polynucleotide or oligonucleotide, e.g., RNA or DNA, located towards the 3'-end of the polynucleotide or oligonucleotide, and may or may not include the 3' most nucleotide(s) or moieties attached to the 3' most nucleotide of the same polynucleotide or oligonucleotide.
  • 5'-end or “5'-region” refer to the portion of a polynucleotide or oligonucleotide, e.g., RNA or DNA, located towards the 5' end of the polynucleotide or oligonucleotide, and may or may not include the 5' most nucleotide(s) or moieties attached to the 5' most nucleotide of the same polynucleotide or oligonucleotide.
  • amplification or “amplifying” refers to the production of additional copies of a nucleic acid sequence. Amplification is typically performed by using, for example, polymerase chain reaction (PCR), reverse transcription RT-PCR, qPCR, qRT- PCR, etc., technologies and/or real time PCR and/or other technologies known in the art.
  • PCR polymerase chain reaction
  • qPCR reverse transcription RT-PCR
  • qRT-PCR qRT-PCR
  • qRT-PCR qRT-PCR
  • qRT-PCR qRT-PCR
  • PCR mixture refers to an aqueous solution comprising the various reagents used to amplify a target nucleic acid, e.g. , RNA, DNA, cDNA, etc., and the like.
  • Amplification may be exponential or linear.
  • a nucleic acid to be amplified may be, for example, either RNA, DNA, cDNA, and the like or equivalents or complements thereof.
  • the sequences amplified in this manner form an "amplicon.” While the exemplary methods described hereinafter relate to amplification using PCR, qPCR, or qRT-PCR, numerous other methods are known in the art for amplification of nucleic acids, e.g., isothermal methods, rolling circle methods, etc.
  • comparing two or more samples means that the same type of sample, e.g., a tissue sample, is used in the comparison.
  • nucleic acid degradation e.g., DNA or RNA
  • comparable samples may be obtained from the same individual at different times.
  • comparable samples may be obtained from different individuals, e.g., a patient and a healthy individual.
  • comparable samples are normalized by a common factor.
  • body fluid samples are typically normalized by volume body fluid and cell-containing samples are normalized by protein content or cell count.
  • determining means determining if a characteristic, trait, or feature is present or not. Assessing may be relative or absolute. Assessing the presence of, for example, includes determining the amount of something present, as well as determining whether it is present or absent.
  • the phrases “difference in the level of or “difference in the amount of refer to differences in the quantity of a particular biomarker, e.g., one or more nucleic acids, e.g., RNAs, in a sample as compared to a control or reference level.
  • the quantity of a particular RNA may be present at an elevated amount or at a decreased amount in samples of patients with a disease compared to a reference level.
  • a "difference in the amount of may be a difference between the level of marker present in a sample as compared to a control.
  • the difference in the amount of is at least about 1%, at least about 2%, at least about 3%, at least about 5%, at least about 10%, at least about 15%, at least about 20%), at least about 25%, at least about 30%>, at least about 35%, at least about 40%>, at least about 50%), at least about 60%>, at least about 75%, at least about 80%> or more.
  • a "difference in the amount of can be a statistically significant difference between the level of the marker present in a sample as compared to a control. For example, a difference can be statistically significant if the measured level of the marker R A falls outside of about 1.0 standard deviations, about 1.5 standard deviations, about 2.0 standard deviations, or about 2.5 stand deviations of the mean of any control or reference group.
  • RNA expression refers to the process of converting genetic information encoded in a gene into RNA, e.g., total RNA, mRNA, miRNA, rRNA, tRNA, or snRNA, through transcription of the gene, i.e., via the enzymatic action of an RNA polymerase, and for protein encoding genes, into protein through translation of mRNA.
  • Gene expression can be regulated at many stages in the process. Up- regulation or activation refers to regulation that increases the production of gene expression products, i.e., RNA or protein, while down-regulation, repression or knock-down refers to regulation that decrease production.
  • Molecules e.g., transcription factors that are involved in up-regulation or down-regulation are often called activators and repressors, respectively.
  • nucleic acid refers to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof and to naturally occurring or synthetic molecules. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, or to any DNA-like or RNA-like material, including natural and/or non-natural bases.
  • microarray refers to an arrangement of a collection of nucleic acids, e.g., nucleotide sequences in a centralized location.
  • Arrays can be on a solid substrate, such as a glass slide, or on a semi-solid substrate, such as nitrocellulose membrane.
  • the nucleotide sequences can be DNA, RNA, or any combination or permutations thereof.
  • the nucleotide sequences can also be partial sequences or fragments from a gene, primers, whole gene sequences, non-coding sequences, coding sequences, published sequences, known sequences, or novel sequences.
  • Tissue microarrays are well known in the art and can be performed as described. See e.g., Camp, R. L., et al, J Clin Oncol, 26, 5630-5637 (2008).
  • a "primer” for amplification is an oligonucleotide that specifically anneals to a target or marker nucleotide sequence and forms a substrate for a nucleic acid polymerase.
  • primer includes "primer pairs" required to amplify a nucleic acid sequence.
  • the 3' nucleotide of the primer can be complementary, identical, and/or hybridize to a target or marker sequence at a corresponding nucleotide position for optimal primer extension by a polymerase.
  • a "forward primer” is a primer that anneals to the anti-sense strand of double stranded DNA (dsDNA) or an appropriate cDNA or RNA or other nucleic acid with similar polarity.
  • a “reverse primer” anneals to the sense- strand of dsDNA or an appropriate cDNA or RNA or other nucleic acids with similar polarity.
  • prognosis refers to a prediction of the probable course and outcome of a clinical condition or disease.
  • a prognosis is usually made by evaluating factors or symptoms of a disease that are indicative of a favorable or unfavorable course or outcome of the disease.
  • determining the prognosis refers to the process by which the skilled artisan can predict the course or outcome of a condition in a patient.
  • prognosis does not refer to the ability to predict the course or outcome of a condition with 100% accuracy.
  • prognosis refers to an increased probability that a certain course or outcome will occur; that is, that a course or outcome is more likely to occur in a patient exhibiting a given condition, when compared to those individuals not exhibiting the condition.
  • prognosis and positive prognosis or “unfavorable prognosis” and “negative prognosis” as used herein are relative terms for the prediction of the probable course and/or likely outcome of a condition or a disease. A favorable or positive prognosis predicts a better outcome for a condition than an unfavorable or negative prognosis.
  • a "favorable prognosis" is an outcome that is relatively better than many other possible prognoses that could be associated with a particular condition, whereas an unfavorable prognosis predicts an outcome that is relatively worse than many other possible prognoses that could be associated with a particular condition.
  • Typical examples of a favorable or positive prognosis include a better than average cure rate, a lower propensity for metastasis, a longer than expected life expectancy, differentiation of a benign process from a cancerous process, and the like.
  • a positive prognosis is one where a patient has a 50% probability of being cured of a particular disease, e.g., cancer, after treatment, while the average patient with the same cancer has only a 25% probability of being cured.
  • a reference level refers to a sample having a level or amount of a substance which may be of interest for comparative purposes.
  • a reference level is the average of the amount of, and/or rate of, intact and/or degraded nucleic acid (e.g., sentinel RNA) from one or more biological samples taken from a control population of one or more healthy (disease-free) subjects.
  • nucleic acid e.g., sentinel RNA
  • the reference level is the amount of, and/or rate of, intact and/or degraded nucleic acid from the same subject at a different time, e.g., prior to the subject developing the disease and/or prior to and/or after and/or during therapy, and/or before and after a sample preparation procedure, and/or before and after sample storage.
  • samples are normalized by a common factor.
  • body fluid samples are normalized by volume body fluid and cell-containing samples are normalized by protein content or cell count.
  • sample biological sample
  • test sample test sample
  • clinical sample laboratory sample
  • biological sample biological sample
  • test sample test sample
  • clinical sample laboratory sample
  • biological sample biological sample
  • biological sample biological sample
  • test sample test sample
  • clinical sample laboratory sample
  • laboratory sample and/or “biospecimen” are used interchangeably and in the broadest sense.
  • a sample may include a bodily tissue or a bodily fluid including but not limited to tissue samples, blood (or a fraction of blood such as plasma or serum), lymph, mucus, tears, urine, stool and saliva.
  • a sample may include an extract from an animal or plant cell, a chromosome, organelle, or a virus.
  • a sample may be a "cell-free” sample, meaning that the volume of cells in the sample are less than about 2% of the total sample volume (preferably less than about 1% of the total sample volume).
  • a sample may comprise RNA, e.g., mRNA or cDNA, any of which may be amplified to provide amplified nucleic acid.
  • a sample may include nucleic acid in solution or bound to a substrate, e.g. , as part of a microarray.
  • a sample may be obtained from any subject or any patient.
  • sample integrity or “sample quality” or “overall quality” are used interchangeably and refer the overall “health” of a sample as it relates to the amount, level, intactness, and/or rate of nucleic acid degradation, e.g., RNA degradation, therein.
  • the “sample integrity” or “sample quality” or “overall quality” can also refer to the ability of the sample to accurately and/or reliably reflect the results for a given assay. Sample integrity or quality, however, is independent of the accuracy or reliability of any particular assay.
  • a biological sample when employing a gene expression panel, may have "optimal” or “good” quality or integrity if the sample possesses the nucleic acids which may be expressed and/or are expressed, e.g., one or more specific mR As.
  • a biological sample when employing a gene expression panel, may have
  • the term "subject” and "patient” are used interchangeably and refer to a mammal, such as a human, but can also be another animal such as a domestic animal, e.g., a dog, cat, or the like, a farm animal, e.g., a cow, a sheep, a pig, a horse, or the like, or a laboratory animal, e.g., a monkey, a rat, a mouse, a rabbit, a guinea pig, or the like.
  • a domestic animal e.g., a dog, cat, or the like
  • a farm animal e.g., a cow, a sheep, a pig, a horse, or the like
  • laboratory animal e.g., a monkey, a rat, a mouse, a rabbit, a guinea pig, or the like.
  • sentinel RNA or “sentinel RNAs” refer to one or more RNA molecules capable of serving as a biomarker for the quality of RNA, such as mRNA, in a biological sample.
  • the sentinel RNA serves as a biomarker for the quality of RNA, such as mRNA, in a biological sample at a given time point.
  • RNA quality in a biological sample See, e.g., Schroeder et al, "The RIN: an RNA integrity number for assigning integrity values to RNA measurements.” BMC molecular biology, 7, 3 (2006).
  • RNA integrity number (RIN).
  • Pol II RNA polymerase II
  • a RIN of > 7 is considered to be “intact” RNA.
  • Auer et al. “Chipping away at the chip bias: RNA degradation in microarray analysis.” Nature genetics, 35, 292-293 (2003).
  • RIN values of less than 7 may however produce spurious microarray results due to reduced transcript probe length and decreased yields prior to hybridization.
  • Thompson et al. "Characterization of the effect of sample quality on high density oligonucleotide microarray data using progressively degraded rat liver RNA.” BMC biotechnology, 7, 57 (2007).
  • RNA transcripts possessing RIN scores of greater than 7.8 can be degraded prior to use in hybridization assays. Popova et al, "Effect of RNA quality on transcript intensity levels in microarray analysis of human post-mortem brain tissues.” BMC genomics, 9, 91 (2008).
  • RNA sequencing RNA-seq
  • 5'-methyl guanosine capped 5'-capped or 5'-m 7 GpppN
  • the degree of degradation in a biological sample can be quantitatively determined using techniques known in the art, e.g., PCR, RT-PCR, and/or qRT-PCR, while avoiding the inconsistencies associated with 3 '-end RNA isolation.
  • PCR PCR, RT-PCR, and/or qRT-PCR
  • sentinel RNA identification of 5'-m 7 GpppN capped, abundantly expressed and rapidly degrading RNAs, termed sentinel RNA, which can be used to accurately measure the quality or integrity of a biological sample.
  • sentinel RNA degradation and the concomitant level of intactness, are assessed to identify abundantly expressed genes, which degrade at a rapid rate, thereby allowing for the absolute and/or relative determination of 3'- and/or 5'-end decay of these candidate RNAs.
  • determinations provide sentinel RNAs as a tool for assessing the overall quality of a biological sample, prior to, for example, clinical assessment and/or gene array analysis.
  • sentinel RNA refers to one or more RNA molecules capable of serving as a biomarker for the quality of RNA, such as mRNA, in a biological sample.
  • sentinel RNA serve as biomarkers for the quality of RNA, such as mRNA, in a biological sample at a given time point.
  • sentinel RNA imparts a mechanism for determining the integrity or quality of a biological sample.
  • sentinel RNAs are abundantly expressed, e.g.
  • tissues and cell types such as, but not limited to, e.g., one or more of muscle cells or tissue, epithelial cells or tissue, endothelia cells or tissue, organ cells or tissue, stem cells or tissue, umbilical vessel cells or tissue, corneal cells or tissue, cardiomyocytes, aortic cells or tissue, corneal epithelial cells or tissue, aortic endothelial cells or tissue, fibroblasts, hair cells or tissue, keratinocytes, melanocytes, adipose cells or tissue, bone cells or tissue, osteoblasts, airway cells or tissue, microvascular cells or tissue, mammary cells or tissue, vascular cells or tissue,
  • chondrocytes placental cells or tissue, plant cells, and the like.
  • one or more sentinel RNAs are tissue specific. Additionally or alternatively, in some embodiments
  • one or more sentinel RNAs do not possess a specific tropism.
  • sentinel RNAs are typically degraded at a rapid, or comparatively measurable, rate, e.g., not degradation resistant. Therefore, sentinel RNAs include, but are not limited to, biologically active or expressed RNA molecules, such as, e.g., exonic RNA (exons), messenger RNA (mRNA), microRNA (miRNA), transfer RNA (tRNA), and/or any RNA molecule possessing a 5'-m 7 GpppN cap.
  • exonic RNA exonic RNA
  • mRNA messenger RNA
  • miRNA microRNA
  • tRNA transfer RNA
  • sentinel RNAs include, for example, biologically inert RNAs, such as, e.g., intronic RNA (introns), intergenic RNA, and the like, or any RNA species derived from the aforementioned classes of RNAs by metabolic processes.
  • biologically inert RNAs such as, e.g., intronic RNA (introns), intergenic RNA, and the like, or any RNA species derived from the aforementioned classes of RNAs by metabolic processes.
  • sentinel RNAs include, but are not limited to, e.g., RNAs from one or more of the following genes or gene products: EIF4G2, STOM, C4BPA, GNB1, TMEM66, NAGS, CALM2, ACTG1, AGT, EIF1, SCARB1, C20orO, CNDP2, CD81, ATP5B, AGXT, EIF4A1, HSP90AB1, AHSG, SARS, CDKN1A, SEPHS2, PSAP, RPL5, TGFBI, CPB2, CCND1, AP2M1, ERGIC3, IBTK, YIF1A, ENOl, UGT2B4, GABARAPL1, KDELR2, RHBDD2, CD63, F9, TRAM1, DHRS3, ZCCHC24, SNRPB, LPCAT3, B2M, ITIH3, RPLP0, CRAT, SERPINA5, ATP5C1, RPL13A, LBP, GSDMD, A
  • the one or more sentinel RNAs are one or both of GNB2L1 and TMBIM6.
  • the sentinel RNAs of the present technology can be directly or indirectly assayed.
  • one or more sentinel RNAs are used as a template for quantitative amplification, e.g., qRT-PCR, according to the methods disclosed herein.
  • the sentinel RNAs described herein, as listed above can be grouped in non-limiting assay panels for use in the methods described herein. In some embodiments, at least from about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 75, 100, or 500 sentinel RNAs to about 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 75, 100, 200, 300, 400, 500, 1,000, or 10,000 sentinel RNAs are group into arrays in accordance with the methods provided herein. Additionally or alternatively, in some embodiments, the one or more sentinel RNAs are assayed in a multiplexed format.
  • compositions, methods and kits described herein may be used to detect nucleic acids associated with various genes using a biological sample obtained from a subject.
  • the biological sample may be from any organism that possesses endogenous nucleic acid (RNA and/or DNA).
  • Biological samples can be obtained by standard procedures and can be used immediately or stored, under conditions appropriate for the type of biological sample, for later use. Methods of obtaining biological samples are well known to those of skill in the art and include, but are not limited to, aspirations, tissue sections, swabs, drawing of blood or other fluids, surgical or needle biopsies, and the like. Additionally or alternatively, in some embodiments, biological samples are obtained pursuant to the instructions or recommendations of a bioassay manufacturer (e.g., MammaPrintTM, ColoPrintTM, etc.) with which the sample is to be tested.
  • a bioassay manufacturer e.g., MammaPrintTM, ColoPrintTM, etc.
  • the starting material for the assays disclosed herein typically include, but are not limited to, one or more clinical samples, which are suspected to contain RNA, e.g., total cellular RNA, and/or one or more sentinel RNAs.
  • the sample may be obtained from a subject or patient.
  • the biological sample in some embodiments, is a cell-containing liquid or a tissue. Samples may include, but are not limited to, biopsies, blood, blood cells, bone marrow, fine needle biopsy samples, peritoneal fluid, amniotic fluid, plasma, pleural fluid, saliva, semen, serum, tissue or tissue homogenates, frozen or paraffin sections of tissue.
  • Samples may also be processed, such as sectioning of tissues, fractionation, purification, or cellular organelle separation.
  • the biological sample includes one or more of blood, plasma, serum, lymph, mucus, sputum, tears, urine, stool, saliva, tissue, hair, animal cells, and plant cells.
  • the sample may contain cells, tissues or fluid obtained from a patient suspected being afflicted with a disease such as, but not limited to, e.g., exogenous diseases, including, but not limited to, bacterial, fungal, prion, and/or viral diseases, e.g., chronic viral hepatitis, and/or endogenous diseases, such as, but not limited to, cancers including, but not limited to, e.g., lymphatic cancers, hematologic cancers, breast cancer, liver cancer, lung cancer, prostate cancer, gastric cancer, endometrial cancer, salivary gland cancer, adrenal cancer, non-small cell lung cancer, pancreatic cancer, renal cancer, ovarian cancer, peritoneal cancer, head and neck cancer, bladder cancer, colorectal cancer, glioblastomas, hematologic tumors, multiple myeloma, acute myelogenous leukemia, and/or colon cancer, and/or metastatic cancers of the same.
  • exogenous diseases including, but not limited to
  • Methods for isolating a particular cell from other cells in a sample include, but are not limited to, Fluorescent Activated Cell Sorting (FACS) as described, for example, in Shapiro, Practical Flow Cytometry, 3rd edition Wiley-Liss; (1995), density gradient centrifugation, or manual separation using micromanipulation methods with microscope assistance.
  • FACS Fluorescent Activated Cell Sorting
  • Exemplary cell separation devices that are useful in the invention include, without limitation, a Beckman JE-6 centrifugal elutriation system, Beckman Coulter EPICS ALTRA computer-controlled Flow Cytometer-cell sorter, Modular Flow Cytometer from Cytomation, Inc., Coulter counter and channelyzer system, density gradient apparatus, cytocentrifuge, Beckman J-6 centrifuge, EPICS V dual laser cell sorter, or EPICS PROFILE flow cytometer.
  • a tissue or population of cells can also be removed by surgical techniques.
  • a biological sample can be prepared for use in the methods of the present invention by lysing a cell that contains one or more desired nucleic acids, e.g., total RNA, mRNA, 5 '-capped RNA, and/or sentinel RNAs.
  • a cell is lysed under conditions that substantially preserve the integrity of the desired nucleic acid.
  • cells can be lysed or subtractions obtained under conditions which stabilize RNA and/or DNA.
  • Such conditions include, for example, cell lysis in strong denaturants, including chaotropic salts such as guanidine thiocyanate, ionic detergents such as sodium dodecyl sulfate, organic solvents such as phenol, high lithium chloride concentrations or other conditions known in the art to be effective in limiting the activity of endogenous RNases during RNA purification.
  • chaotropic salts such as guanidine thiocyanate
  • ionic detergents such as sodium dodecyl sulfate
  • organic solvents such as phenol
  • high lithium chloride concentrations such as RNA purification
  • relatively undamaged nucleic acids such as RNA can be obtained from a cell lysed by an enzyme that degrades the cell wall.
  • Cells lacking a cell wall either naturally or due to enzymatic removal can also be lysed by exposure to osmotic stress.
  • Other conditions that can be used to lyse a cell include exposure to detergents, mechanical disruption,
  • the nucleic acids are separated from proteins and sugars present in the original sample and/or a sample that was subjected to cell lysis. Any purification methods known in the art may be used in the context of the present invention. Those skilled in the art will know or be able to readily determine methods for isolating nucleic acid from a cell, fluid or tissue, such as those described in Sambrook et ah,
  • Nucleic acid sequences in the sample can subsequently be amplified using in vitro amplification, such as PCR or qPCR. Typically, compounds that may inhibit polymerases are removed from the nucleic acids.
  • the biological samples ⁇ e.g., cells, tissues, fluids, nucleic acid, etc. for testing
  • a bioassay manufacturer e.g., MammaPrintTM, ColoPrintTM, etc.
  • RNA isolation and/or extraction is required for a variety of biological assays.
  • Gene expression arrays, RNA sequencing technologies, and tiling arrays, for example, are fundamental tools for developing diagnostic biomarkers of disease, which may require RNA purification. Time consuming annotation of expressed genes and RNA quality assurance in patient samples, however, underlie the problems associated with these approaches.
  • transcript signal values are calculated from probes annealed within 500 bases of the 5'- and/or 3'-end of genes such as, e.g., GAPDH and ACTB.
  • the quality of mRNA is measured as a function of the 375' ratio, wherein quotients of approximately three denote equal amounts of cDNA synthesis from the 5'- and 3 '-ends.
  • Such methods nevertheless typically isolate RNA transcripts from the 3 '-end, via oligo(dT) primers, which hybridize to the poly(A) terminus.
  • 5 '-end RNA levels can be underestimated due to 3 '-end degradation and/or the inability of a reverse transcriptase to processively reach the 5 '-end, i.e., when cDNA synthesis is required.
  • RNA Pol II transcription products which possess a 5'-m 7 GpppN cap (5 '-cap).
  • RNAs include, but are not limited to, for example, exonic mRNA (exons), protein coding mRNA, micro-RNA (miRNA) precursors, and other RNAs which may not encode for specific proteins. See Cai et al, "Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs.” RNA, 10, 1957- 1966 (2004).
  • the isolation and analysis of 5'-capped RNA enables the accurate identification and evaluation of sentinel RNAs, their intactness and/or the 3 -5' and 5 '-3' degradation that occurs in Pol II transcripts because such methods obviate the inconsistencies associated with 3' -RNA isolation.
  • RNA transcripts are present in eukaryotic cells than are currently annotated, yet many appear to lack 3'-poly(A) ends and a majority of these RNAs are Pol II transcripts. See Durtrow et al. (2008). These RNAs likely encode proteins and may also represent non-coding regulatory RNAs.
  • the present technology therefore provides an efficient method of isolating Pol II transcripts by binding their 5 '-caps with a RNA cap binding protein and/or a high-affinity variant of the RNA cap binding protein (4EK119A).
  • RNA sequences in the test sample can subsequently be amplified using in vitro amplification, such as, for example, qRT-PCR.
  • substances, enzymes, and/or compounds that may degrade RNA e.g., RNases, are removed from the sample prior to and/or during RNA isolation and/or extraction.
  • total RNA, mRNA, sentinel RNA, tRNA, rRNA, miRNA, and/or other RNA molecules which may be contained in a biological sample, are isolated.
  • total RNA in some embodiments, is first isolated from a biological sample using techniques known in the art, such as, e.g., Trizol® (Invitrogen), Ribominus®, or other RNA isolation/extraction kits known in the art.
  • Trizol® Invitrogen
  • Ribominus® Ribominus®
  • 5'-capped RNA including, e.g., mRNA and/or sentinel RNA is separated from the total RNA thereby enriching for the mRNA and/or sentinel RNA, for example.
  • the 5 '-capped RNA is isolated from a sample by incubating a tagged cap- binding protein, e.g., eIF-4E, with the total RNA and thereafter purifying the bound complex using methods known in the art, e.g., magnetic or affinity bead isolation and/or chromatography. See, e.g., Folkers et al, "ENCODE tiling array analysis identifies differentially expressed annotated and novel 5 '-capped RNAs in hepatitis C infected liver.” PLoS One, 6, el 4697 (2011). Additionally or alternatively, in some embodiments, a high affinity variant of the cap binding protein is employed to enrich for 5 '-cap-isolated RNA. See Choi et al. (2003).
  • RNA can be isolated from other RNAs in the biological sample to enrich for mRNA and/or sentinel RNA, such that the mRNA and/or sentinel RNA is substantially pure, meaning it is at least about 70%, 75%, 80%, 85%, 90%, 95% pure or more, but typically less than 100%) pure, with respect to other RNA molecules.
  • Various kits for the extraction and/or full or partial isolation and/or purification of total RNA, mRNA, and/or one or more sentinel RNAs, from biological samples are provided herein and/or commercially available and are well known to the skilled artisan.
  • exosome-mediated decay represents one of the primary pathways for mRNA degradation in biological cells. See, e.g., Chen et al., "AU binding proteins recruit the exosome to degrade ARE-containing mRNAs.” Cell, 107, 451-464 (2001). Exosome-mediated decay occurs by 3 -5'
  • AREs AU-rich elements
  • sentinel RNAs are identified by (A) isolating 5' capped mRNA (e.g., as described above in section III.B), and (B) analyzing these RNAs to determine sequence identity, abundance, and/or sequence integrity (e.g., degradation patterns).
  • candidate sentinel RNAs can be identified by nucleic acid sequencing, in conjunction with bioinforomatics programs and publicly available gene expression databases, such as, e.g., GEO Dataset-GSE5364, which contain genetic profiles from a variety of diseased and corresponding healthy samples, and/or databases such as, for example, the Ensembl human genome database, to identify the candidate sentinel RNA sequences.
  • bioinformatics programs can be used to determine the relative abundance and/or integrity (e.g., degradation patterns) of the candidate sentinel RNAs.
  • RNA and/or DNA sequencing allows for the identification of candidate sentinel RNAs the subsequent evaluation of abundance and degradation patterns of these RNAs.
  • RNA and/or DNA sequencing can be performed using methods known in the art, such as, for example, dideoxy chain termination method of Sanger et al. , Proceedings of the National Academy of Sciences USA, 74, 5463-5467 (1977), with modifications by Zimmermann et al, Nucleic Acids Res., 18: 1067 (1990). Sequencing by dideoxy chain termination method can be performed using Thermo Sequenase (Amersham Pharmacia, Piscataway, NJ), Sequenase reagents from US Biochemicals or Sequatherm sequencing kit (Epicenter Technologies, Madison, Wis.). Sequencing may also be carried out by the "RR
  • dRhodamine Terminator Cycle Sequencing Kit from PE Applied Biosystems (product no. 403044, Rothstadt, Germany), Taq DyeDeoxyTM Terminator Cycle Sequencing kit and method (Perkin-Elmer/ Applied Biosystems) in two directions using an Applied Biosystems Model 373 A DNA or in the presence of dye terminators CEQTM Dye Terminator Cycle Sequencing Kit, (Beckman 608000). Additionally or alternatively, sequencing can be performed by a method known as Pyrosequencing (Pyrosequencing, Westborough, Mass.). Detailed protocols for Pyrosequencing can be found in: Alderborn et al., Genome Res. (2000), 10: 1249-1265.
  • R A or DNA sequencing can be performed using hybridization techniques, such as, but not limited to, heteroduplex tracking assays, line probe assays, nucleic acid arrays, nucleic acid arrays (DNA chips), bead arrays, and the like. See U.S. Pat. No. 6,300,063 and U.S. Pat. No. 5,837,832.
  • Massively parallel sequencing, next generation sequencing, and/or deep sequencing are also be used in the methods described herein. See Voelkerding et al. (2009) Clin. Chem. 55(4):641-658; ten Bosch et al. (2008) J. Mol. Diag. 10(6):484-492;
  • Genome Sequence FLX systems from 454 Corporation (a Roche Company)
  • Genome Analyzer from Illumina
  • SOLiD system from Life Technologies.
  • Single molecule massively parallel sequencers include those from, for example, Helicos Biosciences (the Heliscope) and Pacific Biosciences.
  • next generation RNA sequencing is employed to measure the amount, level, and/or presence of one or more candidate sentinel RNAs.
  • Pol II RNA transcripts are analyzed in some embodiments by RNA sequencing using, e.g., an Illumina Genome Analyzer 2 (GA2) and standard protocols for preparing and sequencing libraries representing RNA samples, as known in the art.
  • G2 Illumina Genome Analyzer 2
  • 5'-capped RNAs and/or total RNA is sequenced. Total RNA and/or 5 '-capped RNA- with rRNA removed in some embodiments-can be sequenced using the Ribominus® for RNA-seq kit (Invitrogen).
  • RNAs are fragmented, reverse transcribed to cDNA, and adapted to create a cDNA library.
  • Adapters for cDNAs can be amplified via PCR using, e.g., a Cluster Station (Illumina) and sequenced with an Illumina GA2. See Oler et al., "Human RNA polymerase III transcriptomes and relationships to Pol II promoter chromatin and enhancer-binding factors.” Nat Struct Mol Biol, 17, 620-628 (2010).
  • Nucleic acid sequencing allows for the identification of the candidate sentinel RNA, and provides the information necessary to develop amplification primers which can be used in the methods discussed below.
  • candidate sentinel RNA sequences are aligned with sequences from one or more databases, such as, but not limited to, for example, the NCBI human genome database, NCBI 37.3 of the human genome ⁇ e.g., using the Bowtie aligner), the UCSC Genome Browser, MXSCARNA, Murlet, RNAmine, SCARNA, PHMMTS, PSTAG, Rfold, Stem Kernels, CentroidAlifold, CentroidHomfold, CentroidAlign, miRRim, SCARNA LM, npbfold, RactIP, IPknot, Raccess, Fdur, Rentropy, Rchange GEO Datasets, and/or the Ensembl human genome database, and the like.
  • bioinformatic programs can then be employed to identify the candidate sentinel RNA sequences, and/
  • RNA sequence Reads Per Kilobase of gene per Million reads (“RPKM” or "sequence reads" are obtained and/or performed. Additionally or alternatively, in some embodiments, from about 1,000,000 to about from 10,000,000 RPKM are obtained and/or performed. Additionally or alternatively, in some embodiments 1, 2, 5, 10, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90 or 100 RPKM are obtained and/or performed.
  • RPKM from about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30 or 40 nucleotides to about 10, 15, 20, 30, 40, 50, 100, 200, 300, 400, or 500 nucleotides are aligned to, for example, NCBI 37.3 of the human genome, using the Bowtie aligner. See Oler et al., "Human RNA polymerase III transcriptomes and relationships to Pol II promoter chromatin and enhancer-binding factors.” Nat. Struct. Mol. Biol, 17, 620-628 (2010). Additionally or alternatively, in some embodiments, about 30-50 nucleotides are aligned. Id.
  • Alignments can be filtered and selected based on score ranges for example, based on the number of base mismatches (e.g., between 0 and 3 mismatches).
  • Non-limiting applications such as, for example, "USeqDefmedRegionScanSeqs" can be employed to score genes for relative differential expression.
  • Useq DefinedRegionsScanSeqs determines the genie sequencing reads of a given gene by summing the reads originating from each exon of that gene.
  • DRSS uses the genomic coordinates for each of those three exons to calculate the number of reads from each exon region and sums those reads for that gene. See also, e.g., Nix et ah, "Empirical methods for controlling false positives and estimating confidence in ChlP-Seq peaks.” BMC Bioinformatics, 9, 523 (2008).
  • abundant expression is determined using one or more publicly available gene expression datasets ⁇ e.g., GEO Dataset, containing gene profiles from many solid cancers, GSE5364, Ensembl, etc.) and/or other bioinformatic programs as known in the art.
  • identified sequences ⁇ e.g., candidate sentinel RNAs
  • background levels for read counts of RNA sequencing data are considered to fall between 0.1 and 1 RPKM. The deeper the sequencing depth the more confidence exists in lower background level cutoffs. An RPKM between 0.3-0.4 has been published recently ⁇ see e.g., Blood.
  • abundant expression is defined as three, four, five, six, seven, eight, nine or ten orders of magnitude above background.
  • candidate sentinel RNAs are selected from all genes in the Ensembl human genome.
  • criteria used to identify candidate sentinel RNAs include, for example, expressed genes with about 1, 5, 10, 20, 30, 40, 50, 100, 500, 1000 or more RPKMs. Additionally or alternatively, in some embodiments, candidate sentinel RNAs are selected from samples containing expressed genes with an RPKMs of about > 10. Additionally or alternatively, in some embodiments, candidate sentinel RNAs are selected from samples containing expressed genes with a RPKM of one log above background.
  • sentinel RNAs can include, but are not limited to abundantly expressed genes with about 1 , 5, 10, 20, 30, 40, 50, 100, 500, 1000 or more RPKMs from the 5'- and/or 3'-terminal ends. Additionally or alternatively, in some embodiments, sentinel RNAs contain abundantly expressed genes with about 10-50 or more RPKMs in the 5'- and/or 3'-terminal ends.
  • sequencing analyses of sentinel RNAs are employed to interrogate the 5' and 3'-ends, separately, simultaneously, or sequentially.
  • from about 10, 20, 30, 40, 50, 100, 200, 300, 500, 1000, or 10,000 bases to about 50, 100, 200, 300, 500, 1 ,000; 10,000; or 100,000 bases from the 5*- and/or 3*-ends of one or more sentinel RNAs are analyzed.
  • from about 100 to about 300 bases from the 5' and/or 3'-ends of one or more sentinel RNAs are analyzed.
  • about 200 bases from the 5' and/or 3'-ends of one or more sentinel RNAs are analyzed.
  • sentinel RNAs possess decreasing or increasing 375' and/or 573 ' ratios-at increasing time intervals-relative to static RNAs and/or RNAs which do not possess such ratios. Additionally or alternatively, in some embodiments, sentinel RNAs possess decreasing 375' ratios as time increases.
  • sentinel RNAs processively decay with 3'-5' and/or 5 '-3 ' polarity. Additionally or alternatively, in some embodiments, candidate sentinel RNAs processively decay with 3 '-5' polarity. Additionally or alternatively, in some embodiments, sentinel RNAs processively decay with 3'-5' polarity at a rapid rate.
  • a rapid decay rate is considered a > 20% decrease in sequencing reads on the 3 ' end (200 terminal nucleotides of the 3 ' untranslated end or UTR) compared to the 5 ' end of sentinel RNAs after 5 and 10 minutes at degradation (room temperature in the examples provided). Additionally or alternatively, in some embodiments, a rapid decay rate is defined as a slope of 0.2 between 0 and 10 minutes of degradation.
  • RPKM measurements for identifying sentinel RNAs are selected from sequencing reactions performed after 1 , 2, 3, 4, 5, 10, 15, 20, 30, 40, 50, 75, 100, 200, 500, 1000 or more minutes (min) of sample incubation. Additionally or alternatively, in some embodiments, RPKM measurements for identifying sentinel RNAs are selected from sequencing reactions performed after 5, 10, and/or 15 minutes of sample incubation times.
  • the samples are incubated at about from 0°C, 4°C, 5°C, 10°C, 15°C, 20°C, 25°C, and/or 37°C to about from 4°C, 5°C, 10°C, 15°C, 20°C, 25°C, 35°C, 50°C and/or 100°C and evaluated at specific time points (e.g., such as those described above).
  • the samples are incubated at room temperature and evaluated at specific time points (e.g., such as those described above).
  • sentinel RNAs are identified via degradation pattern analysis of candidate sentinel RNAs.
  • 5' capped RNA sequences are compared to sequences provided in one or more database(s), using e.g., bioinformatics programs, to identify those RNAs which are (1) abundantly expressed and (2) show rapid degradation relative to the other 5' capped RNAs.
  • candidate sentinel RNA degradation patterns are determined by calculating the ratio of the number of sequence reads in a defined number of 3' and/or 5 '-end nucleotides. Additionally or alternatively, in some embodiments, the number of sequence reads in a defined number of 3' and/or 5' end nucleotides is determined at different time points to establish a 3 ' end/5 '-end ratio.
  • the defined number of nucleotides in the 3' and 5 '-ends can be the same or different.
  • the defined number of nucleotides ranges from about 5-1000, about 10-500, about 20-250, and about 30-100.
  • the defined number of nucleotides is about 10, about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90, about 100, about 110, about 120, about 130, about 140, about 150, about 160, about 170, about 180, about 190, about 200, about 210, about 220, about 230, about 240, about 250, about 260, about 270, about 280, about 290, or is about 300 or more.
  • the defined number of nucleotides of the 3' and/or 5'-end is 200.
  • candidate sentinel RNA decay is measured at different time points, e.g., from the time a sample is collected and/or different time points from when a sample is thawed.
  • samples are evaluated for degradation at from about 0.1, 0.5, 1, 2, 3, 4, 5 or 6 seconds, minutes, hours, days or years to about from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 50 or 100 seconds, minutes, hours, days or years.
  • sentinel RNA decay is measured at about 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 11 minutes, 12 minutes, 13 minutes 14 minutes, 15 minutes, 16 minutes, 17 minutes, 18 minutes, 19 minutes, 20 minutes, 30 minutes, 60 minutes, or 90 minutes or more after sample collection or after sample thaw. Additionally or alternatively, in some embodiments, sentinel RNA decay is measured at time points which simulate sample treatment prior to a biological assay. [0093] In a non-limiting exemplary embodiment, candidate sentinel RNAs are identified as follows. Biological samples continaing RNA are sequenced at TO, Tl, T2, and T3 of incubation at a given temperature. Sequencing is performed such that each sample has given number of sequence reads (e.g., 1-10 million sequence reads) for a fixed number of nucleotides (e.g., 10-50) nucleotides. Sequences are evaluated as follows.
  • RNAs with an overall decrease in 375' ratios are identified: (e.g., those RNAs with a slope for the best fit linear line of ⁇ -0.2).
  • RNAs with progressive 3' to 5' degradation are identified (e.g., those RNAs that show a difference in 375' ratio of > 0.2 between TO, Tl and T2 time points).
  • the amount or level of one or more sentinel RNAs present in a biological sample correlates with the biological integrity of the sample, which may subsequently be used in a diagnostic assay. Accordingly, in some aspects, the present methods can be used to measure sentinel RNA levels or amounts in order to facilitate disease diagnosis and/or therapeutic administration.
  • the methods provided herein can be applied to quantify the amount of sentinel RNA decay, and concomitant intactness, in a biological sample at one or more time points.
  • Embodiments of the present technology include methods for determining the amount of one or more sentinel RNA sequences present in a biological sample, and/or degradation thereof, and comparing the result to a reference standard, such as, e.g., a standard curve, normal or healthy control samples, etc.
  • a reference standard such as, e.g., a standard curve, normal or healthy control samples, etc.
  • the difference in the level or amount of one or more sentinel RNA sequences in the biological sample, compared to the reference standard is indicative of the biological sample quality, which may be
  • sentinel R A levels are determined in a biological sample by amplification.
  • the sentinel R As may be biomarkers which pertain to a subject and/or patient and can be used to measure the quality or integrity of a sample, and/or the progressive decrease in the quality or integrity of a biological sample as a function of time.
  • sentinel RNA standards are developed to simulate sample treatment prior to a biological assay (e.g., a MammaPrintTM Oncotype DXTM or ColoPrintTM assay).
  • Standards can be prepared from a separate, comparable biological sample or the same biological sample to be assayed.
  • standards can be prepared and evaluated in advance of the biological assay, using an aliquot of the biological sample to be assayed or a comparable sample.
  • controls or standards can be performed and control or standard information can be provided as values or ranges that indicate sample integrity, to be compared to the sentinel RNA degradation value or range of the biological sample.
  • the biological sample integrity is suspect and should not be used in the bioassay, or if used in the assay, results derived from the suspect biological sample should be critically analyzed.
  • the biological sample shows sentinel RNA degradation that falls within an "acceptable" range or value indicated by the reference standard, the biological sample integrity is good, and the bioassay should proceed.
  • RNA isolation or purification RNA isolation or purification
  • sample storage steps e.g., sample storage steps, and/or the final preparation steps of the sample prior to use in the selected assay application (e.g., reagent addition, incubation, etc.).
  • time, temperature, reagent addition and/or storage of the sample are considered in developing a reference sample(s).
  • sentinel RNA decay is measured to develop a standard from about 0.1, 0.5, 1, 2, 3, 4, 5 or 6 seconds, minutes, hours, days or years to about from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 50 or 100 seconds, minutes, hours, days or years after sample collection and/or after sample thaw (e.g., at RT, or at 4°C).
  • sentinel RNA decay is measured after RNA is isolated from the standard sample, to develop the standard. Additionally or alternatively, in some embodiments, RNA is isolated by methods known in the art, including but not limited to, for example, Trizol® kit and/or 5 '-capped mRNA isolation.
  • the integrity of a biological sample is compared to standard samples containing one or more sentinel RNAs which have been incubated at a given temperature or temperature range (e.g., 0°C, 4°C, 25°C, room temperature (RT), 37°C, etc.). Additionally or alternatively, the incubation of the control sample is at a temperature from about 1, 10, 20, 30 or 40°C to about 20, 30, 40, 50, 60, 70, 80, 90, 100°C or higher. Additionally or alternatively, a standard curve can be generated to facilitate accurate comparative analyses.
  • the integrity of a biological sample can be compared to standard samples containing one or more sentinel RNAs which have been incubated at a selected temperature from about 0.1, 0.5, 1, 2, 3, 4, 5 or 6 seconds, minutes, hours, days or years to about from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 50 or 100 seconds, minutes, hours, days or years.
  • sentinel RNA decay to develop standards is measured using the same methods as used for determining sentinel RNA decay in the biological sample.
  • one or more standard curves can be developed and used as a standards or controls.
  • a control sample is collected and subject to RNase treatment, and/or incubation at a particular temperature, with aliquots being evaluated for sentinel RNA degradation at pre-determined time points (e.g., once per 30 seconds, once per minute, every 2 minutes, every 5 minutes, etc.).
  • a control sample is collected and subject to RNase treatment at increasing concentrations of RNase, and/or incubation at a particular temperature and/or for a specific time (e.g., once per 30 seconds, once per minute, every 2 minutes, every 5 minutes, etc.).
  • control or standard values of sentinel RNA decay are measured using nucleic acid amplification techniques.
  • a control mRNA showing little change in the 375' qPCR ratio with time relative to a sentienl mRNA would be MT-COl (RNA sequencing data and 375' Ratio provided in FIGURE 9).
  • amplification-based assays are used to measure the intactness and/or quantity of sentinel RNAs in a biological sample. As noted above, such assays can be used for control or standard determination and/or for biological sample evaluation. Such assays can rapidly assess RNA integrity in biospecimens prior to downstream gene expression analysis or diagnostic/prognostic testing. In some
  • the respective intactness and quantity of the one or more sentinel RNAs in the biological sample can be determined. Additionally or alternatively, in some embodiments, the intactness of sentinel RNA is determined independent of changes in RNA abundance.
  • RNA from a biological sample is isolated as described above. Additionally or alternatively in some embodiments, RNA from a biological sample is isolated using the 5 '-capped RNA isolation procedures described herein and/or total RNA is used. Additionally or alternatively, in some embodiments, a quantitative assessment of sentinel RNA present in a sample is determined. Additionally or alternatively, in some embodiments, in concert with this assessment, the 3 '-end degradation provides data required for determining whether the one or more sentinel RNAs are intact.
  • the amount of intactness e.g., non-degraded sentinel RNA
  • the amount of sentinel RNA degradation is about from 1, 5, 10, 20, 30, 40, or 50% to about 10, 20, 30, 40, 50, 60, 70, 80, or 90% or more.
  • amplification-based procedures can also be performed to assess the ratio of 375' and/or 573' sentinel RNA in a biological sample.
  • ratios are measured at a single time point or at multiple, different time points.
  • Embodiments of the present technology include, for example, measuring 375' and/or 573' sentinel RNA degradation ratios in a biological sample at a single time.
  • sentinel RNA of a biological sample is measured at various time points, wherein the time points correlate to treatment of the sample, incubation at a specific temperature, etc., as described above.
  • sentinel RNAs in a biological sample possess decreasing 375' ratios as time increases. Additionally or alternatively, in some embodiments, sentinel RNAs processively decay with 3 '-5 polarity. Additionally or alternatively, in some embodiments, sentinel RNAs processively decay with 5 ' - 3 ' polarity. Additionally or alternatively , in some embodiments, sentinel RNAs processively decay in some embodiments with 3 '-5' polarity at a rapid rate.
  • a rapid decay rate is considered a > 20% decrease in sequencing reads on the 3' end (200 terminal nucleotides of the 3' untranslated end or UTR) compared to the 5' end of sentinel RNAs after 5 and 10 minutes at degradation (room temperature in the examples provided). Additionally or alternatively, in some
  • rapid decay rate is defined as a slope of 0.2 between 0 and 10 minutes of degradation.
  • the foregoing embodiments can be measured, for example, using one or more amplification procedures known in the art.
  • RNA and/or DNA can be amplified using nucleic acid amplification techniques well known in the art.
  • nucleic acid amplification techniques include, but are nor limited to, polymerase chain reaction (PCR), reverse transcriptase polymerase chain reaction (RT-PCR), quantitative reverse transcriptase polymerase chain reaction PCR (qRT-PCR), and/or ligase chain reaction.
  • PCR polymerase chain reaction
  • RT-PCR reverse transcriptase polymerase chain reaction
  • qRT-PCR quantitative reverse transcriptase polymerase chain reaction PCR
  • ligase chain reaction See Abravaya, K., et al., Nucleic Acids Research, 23:675-682, (1995), branched DNA signal amplification, Urdea, M.
  • RNA reporters S., et al., AIDS, 7 (suppl 2):S11-S 14, (1993), amplifiable RNA reporters, Q-beta replication, transcription-based amplification, boomerang DNA amplification, strand displacement activation, cycling probe technology, isothermal nucleic acid sequence based amplification (NASBA).
  • NASBA isothermal nucleic acid sequence based amplification
  • PCR is used to amplify a sequence of interest, i.e., a sentinel RNA sequence.
  • PCR is a technique for making many copies of a specific template DNA and/or cDNA sequence.
  • the reaction can include multiple amplification cycles and is initiated using primer sequences that hybridize to the 5 ' and 3 ' ends of the sequence to be copied.
  • the amplification cycle includes an initial denaturation, and typically up to 50 cycles of annealing, strand elongation and strand separation (denaturation).
  • the DNA and/or cDNA sequence between the primers is copied.
  • primers can bind to the copied DNA and/or cDNA as well as the original template sequence, so the total number of copies increases exponentially with time.
  • PCR is performed as according to Whelan et al., J of Clin Micro, 33(3):556- 561 (1995). Briefly, a PCR reaction mixture includes two specific primers, dNTPs, approximately 0.25 U of Taq polymerase, and lx PCR Buffer.
  • Some methods of the present disclosure employ reverse transcription of RNA to cDNA.
  • the method of reverse transcription and amplification may be performed by previously published or recommended procedures.
  • Various reverse transcriptases may be used, including, but not limited to, MMLV RT, RNase H mutants of MMLV RT such as Superscript and Superscript II (Life Technologies, GIBCO BRL, Gaithersburg, Md.), AMV RT, and thermostable reverse transcriptase from Thermus thermophilus .
  • MMLV RT RNase H mutants of MMLV RT
  • AMV RT thermostable reverse transcriptase from Thermus thermophilus
  • one method which may be used to convert RNA to cDNA is the protocol adapted from the Superscript II Preamplification system (Life Technologies, GIBCO BRL, Gaithersburg, Md.; catalog no.
  • qPCR quantitative reverse transcription PCR
  • the methods may include amplifying multiple nucleic acids in sample, also known as “multiplex detection” or “multiplexing.”
  • multiplex PCR refers to PCR, which involves adding more than one set of PCR primers to the reaction in order to detect and quantify multiple nucleic acids, including nucleic acids from one or more target gene markers.
  • multiplexing with an internal control e.g., 18s rRNA, GADPH, or ⁇ -actin
  • an internal control e.g., 18s rRNA, GADPH, or ⁇ -actin
  • Primers can be developed for the amplification and/or quantification assays described herein, for example, using methods well known in the art, e.g., Roche's Universal Probe Library Assay Design Center (Basel, Switzerland). The skilled artisan is capable of designing and preparing primers that are appropriate for amplifying a target or marker sequence.
  • the length of the amplification primers depends on several factors including the nucleotide sequence identity and the temperature at which these nucleic acids are hybridized or used during in vitro nucleic acid amplification. The considerations necessary to determine a preferred length for an amplification primer of a particular sequence identity are well-known to a person of ordinary skill. For example, the length of a short nucleic acid or oligonucleotide can relate to its hybridization specificity or selectivity.
  • primers for detecting one or more sentinel RNA primers may be designed based on the cDNA sequence available for one or more sentinel RNAs including, but are not limited to, e.g., one or more of the following genes or gene products: EIF4G2, STOM, C4BPA, GNB1, TMEM66, NAGS, CALM2, ACTG1, AGT, EIF1, SCARB1, C20orO, CNDP2, CD81, ATP5B, AGXT, EIF4A1, HSP90AB1, AHSG, SARS, CDKN1A, SEPHS2, PSAP, RPL5, TGFBI, CPB2, CCND1, AP2M1, ERGIC3, IBTK, YIF1A, ENOl, UGT2B4, GABARAPL1, KDELR2, RHBDD2, CD63, F9, TRAM1, DHRS3, ZCCHC24, SNRPB, LPCAT3, B2M, ITIH3, RPLP
  • the one or more sentinel RNA primers are provided.
  • primers are provided in the table below.
  • the primers are for one or both of GNB2L1 and TMBIM6.
  • the amplification reactions on the present technology may include a labeled primer or probe, thereby allowing detection of the amplification products corresponding to that primer or probe.
  • the amplification may include a multiplicity of labeled primers or probes; such primers may be distinguishably labeled, allowing the simultaneous detection of multiple amplification products.
  • a primer or probe is labeled with a fluorogenic reporter dye that emits a detectable signal. While a suitable reporter dye is a fluorescent dye, any reporter dye that can be attached to a detection reagent such as an oligonucleotide probe or primer is suitable for use in the invention.
  • Such dyes include, but are not limited to, Acridine, AMCA, BODIPY, Cascade Blue, Cy2, Cy3, Cy5, Cy7, Edans, Eosin, Erythrosin, Fluorescein, 6-Fam, Tet, Joe, Hex, Oregon Green, Rhodamine, Rhodol Green, Tamra, Rox, and Texas Red.
  • amplification is monitored using "real-time" methods.
  • Real time PCR allows for the detection and quantitation of a nucleic acid target.
  • a fluorescent dye which may be a double-strand specific dye, such as SYBR Green® I.
  • other fluorescent dyes e.g., FAM or HEX, may be conjugated to an oligonucleotide probe or a primer.
  • Various instruments capable of performing real time PCR are known in the art and include, for example, ABI Prism® 7900 (Applied Biosystems) and LightCycler® systems (Roche).
  • the fluorescent signal generated at each cycle of PCR is proportional to the amount of PCR product.
  • a plot of fluorescence versus cycle number is used to describe the kinetics of amplification and a fluorescence threshold level is used to define a fractional cycle number related to initial template concentration.
  • enzymatic replication and amplification methods include, but are not limited to, isothermal methods, rolling circle methods, Hot-start PCR, real-time PCR, Allele-specific PCR, Assembly PCR or Polymerase Cycling Assembly (PCA), Asymmetric PCR, Colony PCR, Emulsion PCR, Fast PCR, Real-Time PCR, nucleic acid ligation, Gap Ligation Chain Reaction (Gap LCR), Ligation-mediated PCR,
  • MLPA Multiplex Ligation-dependent Probe Amplification,
  • GEXL-PCR Gap Extension Ligation PCR
  • Q-PCR quantitative PCR
  • QRT-PCR Quantitative real-time PCR
  • multiplex PCR Helicase-dependent amplification
  • Intersequence-specific (ISSR) PCR Inverse PCR
  • LATE-PCR Linear-After-The-Exponential-PCR
  • MSP Methylation-specific PCR
  • Nested PCR Overlap-extension PCR
  • PAN- AC assay Reverse Transcription PCR (RT-PCR), Rapid Amplification of cDNA Ends (RACE PCR), Single molecule
  • SMA PCR amplification PCR
  • TAIL-PCR Thermal asymmetric interlaced PCR
  • Touchdown PCR long PCR
  • nucleic acid sequencing including DNA sequencing and RNA sequencing
  • transcription reverse transcription, duplication, DNA or RNA ligation, and other nucleic acid extension reactions known in the art.
  • 375 '-end expression ratios are generated for each test RNA transcript using formulas for quantification in real-time RT- PCR as described.
  • Pfaffl, M.W. "A new mathematical model for relative quantification in real-time qRT-PCR.” Nucleic acids research, 29, e45 (2001).
  • the formula is as follows:
  • the 375' ratio data equals the efficiency of the target qRT- PCR raised to the power of cycle threshold for the target control subtracted from the cycle threshold of the target sample. Additionally or alternatively, in some embodiments, the ascertained value is subsequently divided by the efficiency of the reference raised to the cycle threshold of the reference control subtracted from the cycle threshold of the reference sample. Additionally or alternatively, in some embodiments, an efficiency of two is employed for all calculations. In some embodiments, exact PCR efficiencies (generally between 1.8 and 2.2) may be calculated for both 5 ' and 3 ' end primer pairs to most accurately calculate 375' ratios.
  • the above formula target and reference are defined as the 3'- and 5 '-end amplicons of the same sentinel RNA, respectively.
  • Cycle thresholds and the 0 minute time point can serve as the cycle threshold control in some embodiments.
  • the sentinel RNAs described herein, as listed above can be grouped in non- limiting assay panels for use in the 375' qRT- PCR assays methods described herein.
  • at least from about 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 75, 100, or 500 sentinel RNAs to about 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 75, 100, 200, 300, 400, 500, 1 ,000, or 10,000 sentinel RNAs are employed for the 3 5' qRT-PCR assays in accordance with the methods provided herein.
  • the 375' qRT-PCR assays described herein are analyzed in comparison to reference standards and/or control samples, from which standard curves were generated for specific tissues and/or assays, as described above. Additionally or alternatively, in some embodiments, the minimum number of sentinel RNAs selected for a 375' qRT-PCR assay to detect degradation of about 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 75, or 90% of the niRNAs in a biological sample are be determined.
  • the minimum number of sentinel RNAs selected is about 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 75, or 90% of the mRNAs in a biological sample. Additionally or alternatively, in some embodiments, the minimum number of sentinel RNAs selected is about 5% of the mRNAs in a biological sample.
  • >3 sentinel RNAs are used to determine the RNA integrity of a biospecimens sample.
  • the exact number of sentinels selected will be determined, in part, by the tissue being sampled as some tissues may have lower overall expression of some sentinels.
  • the number of sentinel RNAs selected is about 10.
  • a panel of sentinel RNAs includes one or more of the following: SERPINA3, B2M, ENOl , GNB2L1 , TMBIM6, PFN1 , MYL6, SAA2, JUNB and TIMP1. 8. Statistical Methods
  • a sentinel RNA may be present at an elevated amount or at a decreased amount in samples of patients having or suspected of having a disease or medical condition compared to a reference level.
  • a "difference of a level” may be a statistically significant difference. For example, a difference may be statistically significant if the measured level of the biomarker falls outside of about 1.0 standard deviations, about 1.5 standard deviations, about 2.0 standard deviations, or about 2.5 stand deviations of the mean of any control or reference group.
  • statistics can be used to determine the validity of the difference or similarity observed between a patient's gene expression level and the reference level.
  • Exemplary statistical analysis methods are described in L.D. Fisher & G. vanBelle, Biostatistics: A Methodology for the Health Sciences (Wiley-lnterscience, NY, 1993). For instance, confidence ("/?") values can be calculated using an unpaired 2-tailed t test, with a difference between groups deemed significant if the p value is less than or equal to 0.05.
  • RNA protection assay RNA protection assay
  • RDA representation difference analysis
  • SAGE serial analysis of gene expression
  • LMF multiplex ligation-mediated amplification with the Luminex FlexMAP
  • WO 91/06678 Kwiatkowski, M., United States Patent Nos. US 6,255,475, US 6,309,836, and US 6639088 and EP1218391; Anazawa, T., et al., United States Patent No. 6242193; Ju, et al., United States Patent No. US 6,664,079; Tsien, R.Y., et al, International Patent Appl. No. WO 91/06678; and Dower, et al, International Patent Appl. No. WO 92/10587.
  • kits employed in the disclosed methods can be packaged into diagnostic kits and the like.
  • Diagnostic kits can include, for example, at least one or more primers specific for one or more sentinel RNAs. Additionally or alternatively, in some embodiments the kit includes nucleotide bases capable of being incorporated into an elongating oligonucleotide by a polymerase. Additionally or alternatively, in some embodiments, the bases are labeled. Additionally or alternatively, in some embodiments, specific labeling reagents can also be included in the kits as disclosed herein.
  • the kit can also contain other suitably packaged reagents and materials needed for amplification, for example, buffers, dNTPs, or polymerizing enzymes, and for detection analysis, for example, enzymes and solid phase extractants.
  • the kits comprise multiple amplification primer sets, wherein at least one of the primers is composed of a sequence complementary to at least a portion of one or more sentinel RNAs, such as, e.g., GNB2L1 and TMBIM6, or any other sentinel RNA as described herein.
  • the kits include controls and/or standards.
  • kits include one or more of the following (consistent with methods, reagents, and compositions discussed above):
  • components for sample purification including a lysis buffer with a chaotropic agent; a glass-fiber filter or column; an elution buffer; a wash buffer; an alcohol solution; and/or a nuclease inhibitor.
  • the components of the kits may be packaged either in aqueous media or in lyophilized form, for example, and will be provided in a suitable container.
  • the components of the kits provided herein may be provided as dried powder(s). Additionally or alternatively, in some embodiments, when reagents and/or components are provided as a dry powder, the powder can be reconstituted by the addition of a suitable solvent.
  • the solvent may also be provided in another container.
  • the container will generally include at least one vial, test tube, flask, bottle, syringe, and/or other container means, into which the solvent is placed, optionally aliquoted.
  • the kits also comprise a second container means for containing a sterile, pharmaceutically acceptable buffer and/or other solvent.
  • Reagents useful for the disclosed methods can be stored in solution or can be lyophilized. When lyophilized, some or all of the reagents can be readily stored in microtiter plate wells for easy use after reconstitution. It is contemplated that any method for lyophilizing reagents known in the art would be suitable for preparing dried down reagents useful for the disclosed methods.
  • kits include control samples or standards, and/or control values or standards.
  • compositions, methods and kits described herein will be understood more readily by reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the present methods and kits.
  • sentinel RNAs represent biomarkers that reflect of the quality of most mRNA contained in a biological sample.
  • Next generation RNA-sequencing was employed as described in the Examples below to analyze 5 '-capped mRNA recovered from human liver biospecimens which were thawed, and subsequently incubated at RT for increasing time periods.
  • candidate sentinel mRNAs were identified using sequencing data by calculating the RPKM ratio in the 3'- and 5 '-terminal ends of transcripts at varying times.
  • RNA samples were obtained with IRB approval and flash frozen with liquid nitrogen and stored at -80°C. Tissue samples were allowed to thaw at room temperature for 0, 5, 10, and 15 min before isolating total RNA.
  • Total RNA was isolated using Trizol® (Invitrogen, Carlsbad, CA) following standard methods. See, e.g., Choi et ah, "Purifying mRNAs with a high-affinity eIF4E mutant identifies the short 3' poly(A) end phenotype.” Proceedings of the National Academy of Sciences of the United States of America, , 7033-7038 (2003). The quality of total RNA was measured using a bioanalyzer from Agilent Technologies (Santa Clara, CA).
  • RNA polymerase II transcripts possessing a 5' m7GpppN cap were purified using a recombinant high affinity variant of eIF4E
  • eIF4EKl 19A which binds to the 5'-cap with at least a tenfold higher affinity than the wild- type protein.
  • Spivak-Kroizman et al. "Mutations in the S4-H2 loop of eIF4E which increase the affinity for m7GTP.”
  • Friedland et al "A mutant of eukaryotic protein synthesis initiation factor eIF4E(Kl 19A) has an increased binding affinity for both m7G cap analogues and eIF4G peptides.” Biochemistry, 44, 4546-4550 (2005).
  • GST-tagged eIF4EKl 19A protein bound to glutathione-agarose beads was used to purify 5'-capped RNA as described. See, e.g., Choi et al. (2003).
  • RNA polymerase II transcripts were analyzed by RNA sequencing with an Illumina Genome Analyzer 2 (GA2) and using standard protocols for preparing and sequencing libraries representing RNA samples. 5'-capped RNAs with rRNA removed (Ribominus® for RNA-seq kit, Invitrogen, Carlsbad, CA) were fragmented, reverse transcribed to cDNA, and adapters added to create a cDNA library. cDNAs with adapters were amplified by PCR using a Cluster Station (Illumina, San Diego, CA) and sequenced with an Illumina GA2.
  • GA2 Illumina Genome Analyzer 2
  • the bioinformatic criteria used to identify candidate sentinel RNAs were as follows: all genes - 36,615 genes in the Ensembl human genome 19 March 2009 build; expressed genes - 12,166 genes with 10 or more sequencing reads in the 15 minute sample; abundantly expressed genes - 4,877 genes with 50 or more reads in the 15 minute sample; abundantly expressed genes with significant 5' and 3' transcription - 706 genes with 25 or more reads in the terminal 200 bp of their 5' and 3' ends at 0 minutes and 25 or more reads in their 5' end after 5, 10, and 15 minutes; RNAs with an overall decrease in 375' ratios - 565 RNAs with a slope for the best fit linear line of ⁇ -0.2; and RNAs with progressive 3' to 5' degradation - 304 RNAs showed a difference in 375' ratio of > 0.2 between 0, 5, and 10 minute time points. After ten minutes half of these transcripts (148 or 49%) had ⁇ 25 reads in their
  • the cDNA was produced using random hexamers from two different preparations of RNA: 5 '-cap dependent RNA isolation and total RNA treated with
  • Ribominus® PCR was performed in 96-well plates in a final reaction volume of 20 ⁇ .
  • RNA Integrity Number (RIN) values of 9.5, 8.9, 7.9, and 6.7, respectively (see Figure 1). These values fall within the recommended guidelines for intact high quality RNA that would be examined by gene arrays, RNA sequencing (RNA-seq), and in clinical diagnostic or prognostic gene array testing. See, e.g., Schroeder et al., "The RIN: an RNA integrity number for assigning integrity values to RNA
  • the vertical bar represents the total number of reads for a 36 nucleotide sequence of isolated 5'- capped RNA, which was aligned with the corresponding genomic region, as provided (Hg 19, 2009).
  • Rapidly degrading transcripts such as, e.g., JUNB ⁇ see Figure 4B
  • 33%, 60%) and 78% reductions in JUNB 3' reads were observed after 5, 10 and 15 min, respectively.
  • PFN1 decreased by 39%>, 66%>, and 86%> after 5, 10 and 15 min, respectively (Figure 4A).
  • HIST1H1E see Figure 4C
  • MT-BCOl see Figure 4D
  • Candidate sentinel mRNAs were identified as described in Example 1, i.e., by employing RNA sequencing data and calculating the ratio of sequence reads in the last 200 3 '-end bases to the first 200 5 '-end bases (3' end/5' end ratio), at various time points. A total of 304 of candidate sentinel RNAs were identified as shown below in Table 2.
  • RNAs that reflect the integrity of most mRNAs in a sample is useful in developing improved and more rapid measures of RNA integrity in biospecimens.
  • 304 candidate sentinel mRNA transcripts were identified that were rapidly degraded in a 3' to 5' processive order, by mining the Pol II RNA-seq dataset described with specific criteria. These RNAs, or variants thereof, can be used to determine the integrity of a biological sample.
  • a candidate sentinel RNA is defined as a protein coding transcript that has specific expression criteria and shows a difference in 375' sequence reads of >0.2 between 0.5 and 10 minutes (see Materials and Methods).
  • mitochondrial transcript MT-BC01
  • HIST1H1E is another mRNA that showed very slow degradation with time ( Figure 4C).
  • Such transcripts provide useful controls.
  • qRT-PCR is employed as follows to facilitate the determination of biological sample quality via sentinel RNA analysis.
  • a standard curve is prepared using a fresh tissue of interest and incubating at room temperature for 0, 10, 20, 40, 60 minutes. Each time point is divided into three sets thereby allowing for in parallel analysis through standard gene microarrays, such as, e.g., Affymetrix, to measure mRNAs of the most expressed genes, while performing pair-wise differential gene expression analyses.
  • standard gene microarrays such as, e.g., Affymetrix
  • the number of genes that are determined to be differentially expressed are a direct measure of a "false positives" due to, e.g., sample degradation at the thresholds used to select the differentially expressed genes.
  • differentially expressed genes at a false discovery rate ("FDR") of 1% and 2X difference.
  • FDR false discovery rate
  • the FDR of a sentinel RNA is ⁇ 0.1.
  • threshold stringency is increased to accommodate acceptable FDR.
  • qRT-PCR is performed on tissue specific sentinel RNAs at each time point. Initially, this is performed at each time point with an unknown RNA set. The 375' ratio is calculated for each gene, at each time point, after converting the 3 '-end terminus and 5 '-end terminus cycle number to relative abundance. As such, at each time point an array of 375' ratios is obtained. Next the test sample is measured against a standard curve by calculating pair-wise Euclidian distances. The time points most closely associated with the test sample serve to score the sample in minutes of degradation.
  • RNA integrity is empirically determined for each application, e.g., using a fresh sample of a known quality of RNA, while subjecting such a sample to degradation using RNase and the like, and subsequently assaying the sample. 5.
  • RNA integrity is empirically determined for each application, e.g., using a fresh sample of a known quality of RNA, while subjecting such a sample to degradation using RNase and the like, and subsequently assaying the sample. 5.
  • each range discussed herein can be readily broken down into a lower third, middle third and upper third, etc.
  • all language such as “up to,” “at least,” “greater than,” “less than,” and the like include the number recited and refer to ranges which can be subsequently broken down into subranges as discussed above.
  • a range includes each individual member.
  • a group having 1-3 nucleotides refers to groups having 1, 2, or 3 nucleotides.
  • a group having 1-5 nucleotides refers to groups having 1, 2, 3, 4, or 5 nucleotides, and so forth.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés, des trousses et des composants pour l'identification et la détection de molécules d'acide nucléique, telles que dans un échantillon biologique. Les compositions, procédés et trousses sont utiles pour estimer l'intégrité d'un échantillon biologique.
PCT/US2012/052519 2011-08-31 2012-08-27 Procédés de détermination de l'intégrité d'un échantillon biologique WO2013033019A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161575922P 2011-08-31 2011-08-31
US61/575,922 2011-08-31
US201261601402P 2012-02-21 2012-02-21
US61/601,402 2012-02-21

Publications (1)

Publication Number Publication Date
WO2013033019A1 true WO2013033019A1 (fr) 2013-03-07

Family

ID=47756788

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/052519 WO2013033019A1 (fr) 2011-08-31 2012-08-27 Procédés de détermination de l'intégrité d'un échantillon biologique

Country Status (1)

Country Link
WO (1) WO2013033019A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016016065A1 (fr) * 2014-07-28 2016-02-04 Metanomics Health Gmbh Moyens et procédés pour évaluer la qualité d'un échantillon biologique
CN107543929A (zh) * 2016-06-23 2018-01-05 中国医学科学院肿瘤医院 基于蛋白标志物hsp90ab1诊断肺癌患者的试剂盒
CN108026584A (zh) * 2015-09-11 2018-05-11 适体科学株式会社 非小细胞肺癌诊断用蛋白质生物标志物组及利用其的非小细胞肺癌诊断方法
CN112795579A (zh) * 2019-12-25 2021-05-14 四川省人民医院 克山病基因筛查试剂盒
CN113109569A (zh) * 2021-03-05 2021-07-13 李朴 Gsdmd作为生物标志物在胸腔积液相关疾病鉴别诊断及疗效评估上的用途
US11686731B2 (en) 2015-01-05 2023-06-27 Ian Mills Prostate cancer markers and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876937A (en) * 1995-07-03 1999-03-02 Akzo Nobel N.V. Method for determining the integrity of nucleic acid
WO2001062981A1 (fr) * 2000-02-25 2001-08-30 Montclair Group Plate-forme destinee a la decouverte de genes bacteriens impliques dans la modification d'arn
US20060281108A1 (en) * 2005-05-03 2006-12-14 Althea Technologies, Inc. Compositions and methods for the analysis of degraded nucleic acids
US20100057371A1 (en) * 2008-08-29 2010-03-04 Bio-Rad Laboratories, Inc. Determination of the integrity of rna

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876937A (en) * 1995-07-03 1999-03-02 Akzo Nobel N.V. Method for determining the integrity of nucleic acid
WO2001062981A1 (fr) * 2000-02-25 2001-08-30 Montclair Group Plate-forme destinee a la decouverte de genes bacteriens impliques dans la modification d'arn
US20060281108A1 (en) * 2005-05-03 2006-12-14 Althea Technologies, Inc. Compositions and methods for the analysis of degraded nucleic acids
US20100057371A1 (en) * 2008-08-29 2010-03-04 Bio-Rad Laboratories, Inc. Determination of the integrity of rna

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NOLAN, TANIA ET AL.: "Quantification of mRNA using real-time RT-PCR", NATURE PROTOCOLS, vol. L, no. 3, 2006, pages 1559 - 1582, XP009084519, DOI: doi:10.1038/nprot.2006.236 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016016065A1 (fr) * 2014-07-28 2016-02-04 Metanomics Health Gmbh Moyens et procédés pour évaluer la qualité d'un échantillon biologique
US11686731B2 (en) 2015-01-05 2023-06-27 Ian Mills Prostate cancer markers and uses thereof
CN108026584A (zh) * 2015-09-11 2018-05-11 适体科学株式会社 非小细胞肺癌诊断用蛋白质生物标志物组及利用其的非小细胞肺癌诊断方法
CN108026584B (zh) * 2015-09-11 2021-12-10 适体科学株式会社 非小细胞肺癌诊断用蛋白质生物标志物组及利用其的非小细胞肺癌诊断方法
CN107543929A (zh) * 2016-06-23 2018-01-05 中国医学科学院肿瘤医院 基于蛋白标志物hsp90ab1诊断肺癌患者的试剂盒
CN112795579A (zh) * 2019-12-25 2021-05-14 四川省人民医院 克山病基因筛查试剂盒
CN112795579B (zh) * 2019-12-25 2022-03-18 四川省人民医院 克山病基因筛查试剂盒
CN113109569A (zh) * 2021-03-05 2021-07-13 李朴 Gsdmd作为生物标志物在胸腔积液相关疾病鉴别诊断及疗效评估上的用途
CN113109569B (zh) * 2021-03-05 2022-08-19 李朴 Gsdmd作为生物标志物在胸腔积液相关疾病鉴别诊断及疗效评估上的用途

Similar Documents

Publication Publication Date Title
JP6246845B2 (ja) 遺伝子発現を用いた前立腺癌の予後を定量化する方法
CN105917008B (zh) 用于前列腺癌复发的预后的基因表达面板
JP4606879B2 (ja) Ｅｇｆｒ陽性癌の遺伝子発現プロファイリング
US7914988B1 (en) Gene expression profiles to predict relapse of prostate cancer
US20230366034A1 (en) Compositions and methods for diagnosing lung cancers using gene expression profiles
US20140220580A1 (en) Biomarker compositions and methods
JP2009529880A (ja) 原発細胞の増殖
CA2865335A1 (fr) Compositions de biomarqueurs et procedes associes
JP2006506093A5 (fr)
JP2015503356A (ja) 末梢血中で、がんによって変化したｒｎａを検出するシステムおよび方法
Parsons et al. Circulating plasma tumor DNA
EP3481951A1 (fr) Marqueurs de méthylation spécifiques du cancer du côlon et utilisations de ces marqueurs
CN114945687A (zh) 对疑似具有肺瘤变的受试者中的甲基化dna、rna和蛋白质的表征
WO2018009703A1 (fr) Marqueurs de méthylation du cancer du sein et de l'ovaire et leurs utilisations
Gimondi et al. Circulating miRNA panel for prediction of acute graft-versus-host disease in lymphoma patients undergoing matched unrelated hematopoietic stem cell transplantation
WO2013033019A1 (fr) Procédés de détermination de l'intégrité d'un échantillon biologique
Jacobson et al. Gene expression analysis using long-term preserved formalin-fixed and paraffin-embedded tissue of non-small cell lung cancer
US9347088B2 (en) Molecular signature of liver tumor grade and use to evaluate prognosis and therapeutic regimen
KR20230003560A (ko) 대장암의 조기 발견, 치료 반응의 예측 및 예후 방법
US20160222461A1 (en) Methods and kits for diagnosing the prognosis of cancer patients
Li et al. The cornerstone of integrating circulating tumor DNA into cancer management
CN106676191A (zh) 一种用于结肠腺癌的分子标志物
CN104131113B (zh) 一种miRNA检测试剂盒及其应用
AU2015227398A1 (en) Method for using gene expression to determine prognosis of prostate cancer
KR20140125647A (ko) 조기 유방암 예후 예측 진단용 자동화 시스템

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12827219

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12827219

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载